LifeStance Health Group, Inc.
NASDAQ:LFSTMedical - Care Facilities
+$0.17 today
- Market cap
- $5.24B
- Beta
- 1.19
- P/E (TTM)
- 146.6
- EPS (TTM)
- $0.06
Volume 6.60M
Average 3.91M
LFST Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
LifeStance Health Group, Inc.NASDAQ: LFST
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue grows in line with its trailing trend
Q2 FY2026 cost of revenue of $282.31M rose 19.2% year over year, ahead of the +18.5% change in trailing-twelve-month cost of revenue. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at +15.7% a year.
Context
- Cost of revenue amounted to 67.6% of revenue in FY2025, down 0.2 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +19.2% holds above the trailing-twelve-month pace of +18.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 963.19M USD
- Year-over-year change
- +13.5%
- 4-year CAGR
- +19.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 963.19M | +13.5% |
| FY2024 | 2024-12-31 | 848.57M | +12.6% |
| FY2023 | 2023-12-31 | 753.57M | +21.1% |
| FY2022 | 2022-12-31 | 622.53M | +33.6% |
| FY2021 | 2021-12-31 | 466M | — |
Cost of Revenue vs competitors
How LFST compares with its peers on the latest reported figures
- LFST's LTM Jun 2026 cost of revenue of $1.05B is the 6th highest of the 7 companies compared; the peer median is $1.91B.
- Its year-over-year change of +18.5% is the 5th highest of 7, against a peer median of +24.9%.
- Cost of revenue amounts to 66.4% of revenue for LFST, versus a peer median of 51.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $13.34B | +22.6% | +21.4% | 87.5% | |
| LTM Jun 2026 | $2.18B | +27.2% | +16.1% | 92.4% | |
| LTM Sep 2026 | $2.14B | +252.6% | +200.9% | 62.7% | |
| LTM Jun 2026 | $1.69B | +4.3% | +4.0% | 9.3% | |
| LTM Sep 2026 | $1.13B | +105.4% | +73.2% | 39.5% | |
| LTM Jun 2026 | $1.05B | +18.5% | +15.7% | 66.4% | |
| LTM Mar 2026 | $30.96M | +10.1% | +28.2% | 14.1% | |
| Peer median (excluding LFST) | $1.91B | +24.9% | +24.8% | 51.1% | |
Competitors are the stored peer set for LFST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 667.51M | 859.54M | 1.06B | 1.25B | 1.42B |
| Cost of Revenue | 466M | 622.53M | 753.57M | 848.57M | 963.19M |
| Gross Profit | 201.51M | 237.02M | 302.1M | 402.4M | 461.1M |
| Gross Margin | 30.2% | 27.6% | 28.6% | 32.2% | 32.4% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 433.73M | 377.99M | 410.79M | 363.06M | 382.2M |
| Operating Expenses | 487.86M | 447.19M | 491.23M | 434.01M | 436.95M |
| Depreciation & Amortization | 54.14M | 69.2M | 80.44M | 70.95M | 54.75M |
| EBITDA | (240.06M) | (143.6M) | (104.93M) | 39.87M | 78.78M |
| EBITDA Margin | -36.0% | -16.7% | -9.9% | 3.2% | 5.5% |
| Operating Income | (286.35M) | (210.17M) | (189.13M) | (31.61M) | 24.15M |
| Operating Margin | -42.9% | -24.5% | -17.9% | -2.5% | 1.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 38.91M | 19.93M | 21.22M | 26.54M | 11.66M |
| Other Income / Expenses | (46.75M) | (22.56M) | (17.45M) | (26M) | (11.79M) |
| Income Before Tax | (333.11M) | (232.73M) | (206.58M) | (57.61M) | 12.36M |
| Pre-Tax Margin | -49.9% | -27.1% | -19.6% | -4.6% | 0.9% |
| Income Tax Expense | (25.91M) | (17.17M) | (20.32M) | (170K) | 2.7M |
| Net Income | (307.2M) | (215.56M) | (186.26M) | (57.44M) | 9.66M |
| Net Margin | -46.0% | -25.1% | -17.6% | -4.6% | 0.7% |
| EPS (Basic) | (1.05) | (0.61) | (0.51) | (0.15) | 0.03 |
| EPS (Diluted) | (1.05) | (0.61) | (0.51) | (0.15) | 0.02 |
| Weighted Avg Shares | 327.52M | 355.28M | 367.46M | 379.15M | 386.02M |
| Weighted Avg Shares (Diluted) | 327.52M | 355.28M | 367.46M | 379.15M | 391.14M |
LifeStance Health Group, Inc.
NASDAQ:LFST
Intrinsic Alpha fair value
Locked
Current Price
$13.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.